2024 China International Bioindustry Expo to Be Held in Hainan This November – Call for Exhibitors and Attendees!

Exhibition Introduction ‹‹‹‹‹‹

As a key thematic exhibition held concurrently with the 2024 China International Biopharmaceutical Conference, the Hainan International Pharmaceutical and Health Products Exhibition, and the 8th Hainan International Health Industry Expo, the 2024 China Bio-Industry Expo (BIOEXPO) leverages its robust platform advantages by adopting a “forum + exhibition” model. It establishes a high-level dialogue platform for government officials, experts, and enterprises, showcases cutting-edge technologies and new products in the industry, facilitates pharmaceutical transactions and project investments, drives institutional integrated innovation in the pharmaceutical sector, promotes high-quality development of China’s pharmaceutical industry, and aims to build a health industry “Silicon Valley” based in the Hainan Free Trade Port, serving the entire country and engaging globally.

At that time, the Organizing Committee will invite over 1,000 attendees, including leaders from relevant national ministries and commissions, officials from the Hainan Provincial Government, academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering, experts and scholars, senior executives from pharmaceutical companies, and managers of domestic and international medical institutions. Participants will engage in discussions on topics such as national policies, institutional innovation, and cutting-edge technologies, jointly strategizing for the development of the biopharmaceutical industry, building a complete industrial ecosystem, promoting high-quality industrial growth, and fostering new cooperation between domestic and international biopharmaceutical sectors. With attendance exceeding 50,000, this biopharmaceutical industry conference operates through three major systems—“Exhibition, Conference, and Activities”—and serves Chinese biopharmaceutical enterprises across multiple dimensions, including technology sharing, project collaboration, supply-procurement matchmaking, and talent exchange.

BIOEXPO 2024 features innovative enterprises specializing in novel drugs, biopharmaceuticals, biological products, radiolabeled antibody-drug conjugates, cell therapies, gene therapies, and nucleic acid-based therapeutics. It also showcases professional categories such as raw materials, reagents, consumables, instruments, equipment, and technical services. By fostering synergy across the upstream and downstream sectors, the exhibition builds a diversified ecosystem integrating government, clinical practice, industry, research, and capital.

Here, we look forward to your participation with an elite team, a polished and impressive presence, and cutting-edge products for demonstration, as we have prepared everything for you—business opportunities await!

Organizational Structure (Proposed) ‹‹‹‹‹‹

Guiding Organizations:

Central Committee of the Chinese Peasants and Workers Democratic Party

Hainan Provincial People's Government

Organizer:

Chinese Society for Biotechnology

Supporting Organizations:

Chinese Medical Association

Chinese Preventive Medicine Association

Hainan Provincial Department of Science and Technology

Hainan Provincial Department of Industry and Information Technology

People's Governments of All Cities and Counties in Hainan Province

Hainan University

Organizer:

Guangdong Benchmark Exhibition Co., Ltd.

Guangzhou Linghang Exhibition Co., Ltd.

Co-organizers:

Special Committee on Life Science Instruments, Chinese Society for Biotechnology

Precision Medicine Professional Committee of the Chinese Society for Biotechnology

Synthetic Biology Branch of the Chinese Society for Biotechnology

Cell Analysis Professional Committee of the Chinese Society for Biotechnology

Stem Cell and Tissue Engineering Professional Committee of the Chinese Society for Biotechnology

Antibody Engineering Professional Committee, Chinese Society for Biotechnology

Branch of Biosensing, Biochips, and Nanobiotechnology, Chinese Society for Biotechnology

Medical Biotechnology Committee of the Chinese Society for Biotechnology

Computational Biology and Bioinformatics Professional Committee of the Chinese Society for Biotechnology

The Chinese Society of Biotechnology, Committee on Big Data in Biopharmaceuticals

The Translational Medicine Professional Committee of the Chinese Society for Biotechnology

Committee on Microbiome Science and Technology, Chinese Society for Biotechnology

Chinese Society for Biotechnology, Committee on Animal Biotechnology

Committee on Food Biotechnology, Chinese Society for Biotechnology

System Biomedicine Professional Committee of the Chinese Society for Biotechnology

The Professional Committee on Bio-based Materials of the Chinese Society for Biotechnology

Chinese Society for Biotechnology, Phage Technology Professional Committee

Up‹‹‹‹‹‹ Leaders Present at the Session

Main Event Schedule at the Conference ‹‹‹‹‹‹

(I) Opening Ceremony

Leaders from the guiding, organizing, undertaking, supporting, and co-organizing units, exhibition delegations from all provinces, autonomous regions, and municipalities, as well as participating exhibitors and attendees, are invited to attend. The event features program performances, speeches by leaders and distinguished guests, and other segments. Hainan Satellite TV will provide a live broadcast of the entire opening ceremony.

(II) Main Forum 1: The 8th China International Summit on Healthcare Industry & International “One Health” Conference 2024

Scale:Approximately 1,000 people

Content:Co-hosted by the Central Committee of the Chinese Peasants and Workers Democratic Party (CPWDP) and the Chinese Center for Disease Control and Prevention (China CDC), the forum featured two main segments: keynote speeches and panel discussions. The event brought together more than 1,000 participants, including leaders from the CPWDP Central Committee, the National Health Commission, and the Hainan Provincial People’s Government; heads of the World Health Organization; academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering; Masters of Traditional Chinese Medicine; CEOs of Fortune Global 500 companies; experts and scholars; officials from relevant government departments across various provinces and municipalities; representatives of industry organizations; executives from international healthcare institutions; and enterprise representatives. Focusing on the high-quality development of the medical and health industry, the forum explored new opportunities, challenges, and trends facing the sector. By convening an industry “think tank,” it aimed to summarize experiences, plan for the future, build consensus, and promote the deep integration of the industrial chain, innovation chain, and service chain.

Proposed List of Invited Guests

He Wei, Vice Chairperson of the Standing Committee of the 14th National People's Congress and Chairman of the Central Committee of the Chinese Peasants and Workers Democratic Party

Yang Zhen, Vice Chairperson of the 14th National Committee of the Chinese People's Political Consultative Conference and Executive Vice Chairperson of the Central Committee of the Chinese Peasants and Workers Democratic Party

FengFeiSecretary of the Hainan Provincial Committee of the Communist Party of China

Li Bin, Deputy Director and Party Group Member of the National Health Commission

Xie Jing, Vice Governor of the People's Government of Hainan Province

Luo Qingming, Academician of the Chinese Academy of Sciences, Vice Chairman of the Hainan Provincial Committee of the Chinese People's Political Consultative Conference

Margaret Chan, Director-General Emeritus of the World Health Organization and Dean of the Vanke School of Public Health at Tsinghua University

High   Fu, Academician of the Chinese Academy of Sciences

Zhang Boli, Recipient of the National Honorary Title “People’s Hero,” Academician of the Chinese Academy of Engineering

Li Lanjuan, Academician of the Chinese Academy of Engineering, President of Boao Super Hospital

Wang Chen, Academician of the Chinese Academy of Engineering, Vice President of the Chinese Hospital Association

Kang Le, Academician of the Chinese Academy of Sciences

Tong Xiaolin, Academician of the Chinese Academy of Sciences

Xie Mingyong, Academician of the Chinese Academy of Engineering, Professor at Nanchang University

Zhang Wenhong, Director of the National Center for Infectious Diseases

Zhou Xiaonong, Director of the National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention

Wang Guangji, Academician of the Chinese Academy of Engineering, Expert in Pharmacokinetics

Fu Xiaobing, Academician of the Chinese Academy of Engineering, Expert in Trauma and Tissue Repair and Regenerative Medicine

Liu Liang, Academician of the Chinese Academy of Engineering, President of Guangzhou University of Chinese Medicine, and Dean of the Institute of Integrated Traditional Chinese and Western Medicine Innovation

Yang Baofeng, Academician of the Chinese Academy of Engineering, Expert in Pharmacology

Yang Shengli, Academician of the Chinese Academy of Engineering, Biotechnology Expert

Chen Yong, Academician of the Chinese Academy of Engineering, Chairman of the Guangdong Association for Science and Technology

Lin Dongxin, Academician of the Chinese Academy of Engineering, Director of the China Anti-Cancer Association

Dong Jiahong, Academician of the Chinese Academy of Engineering, Executive President of Beijing Tsinghua Changgung Hospital

Cheng Jing, Academician of the Chinese Academy of Engineering, Expert in Medical Biophysics and Biochips

Zeng Yixin, Academician of the Chinese Academy of Sciences, Oncologist

Jian Qimin, Academician of the Chinese Academy of Engineering, Director of Peking University Health Science Center

Fan Jia, Academician of the Chinese Academy of Sciences, President of Zhongshan Hospital, Fudan University

Yuan Taize, Deputy Director of the Department of Radiation Oncology, Guangzhou Taihe Cancer Hospital

Ke Zunfu, Deputy Director, Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University

Peng Huachang, Research Group Leader, Department of Drugs and Vaccines, Guangzhou Laboratory

Ye Wencai, Vice President of Jinan University

Ouyang Ping, Director of the Health Management Center, Nanfang Hospital, Southern Medical University

Qiao Youlin, Professor at Peking Union Medical College; Member of the WHO Expert Group on the Global Elimination of Cervical Cancer

Tian Yantao, Director of the Pancreatic and Gastric Surgery Ward, Cancer Hospital, Chinese Academy of Medical Sciences

Ding Kefeng, Vice President of the Second Affiliated Hospital of Zhejiang University School of Medicine

Zhang Chenyu, Professor of Biochemistry at Nanjing University and Dean of the School of Life Sciences

(3) Main Forum 2: China International Summit on Biopharmaceutical Innovation

Scale:Approximately 1,000 people

Content:Co-hosted by the China Chamber of Commerce for Import and Export of Medicines and Health Products, the Chinese Society for Biotechnology, and the Chinese Hospital Association, the conference will feature two main segments: keynote speeches and panel discussions. It is expected to attract over 1,000 attendees, including leaders from the National Health Commission, the National Medical Products Administration, and the Hainan Provincial People’s Government; academicians from the Chinese Academy of Sciences and the Chinese Academy of Engineering; senior executives from pharmaceutical companies; experts and scholars; and administrators of domestic and international medical institutions. Participants will interpret national policies, jointly explore hot topics in biopharmaceutical technological innovation, discuss strategies for the development of the biopharmaceutical industry, build a comprehensive industrial ecosystem, promote high-quality industrial development, and foster domestic and international pharmaceutical innovation and cooperation.

(IV) Parallel Forum 1: China Digital Therapeutics Development Summit

Scale:Approximately 200 people

Content:Hosted by the China Association for the Promotion of Rehabilitation Technology Translation and Development, and co-organized with institutions such as the China Academy of Information and Communications Technology (CAICT) under the Ministry of Industry and Information Technology, the Institute of Automation of the Chinese Academy of Sciences, and relevant rehabilitation hospitals, this event invites leaders from regulatory authorities, industry scholars and experts, and representatives from leading domestic and international digital therapeutics companies to engage in in-depth discussions on how digital technologies can empower the healthcare industry and promote the deep integration of digital technology with healthcare.

(5) Parallel Forum 2: “Belt and Road” International Medical and Health Cooperation Forum

Scale:Approximately 200 people

Content:Co-hosted by the China Chamber of Commerce for Import and Export of Medicines and Health Products and the Chinese Hospital Association, the event plans to invite leaders from relevant domestic and foreign health administrative agencies, industry leaders, hospital administrators, academic experts, and pharmaceutical company representatives.

(6) Parallel Forum 3: Investment Promotion Conference for the Transfer and Commercialization of Achievements in Major New Drug Development

Scale:Approximately 150 people

Content:Co-hosted by the Hainan Provincial Department of Science and Technology in collaboration with relevant entities, the event invites leaders from the healthcare security, health commission, drug administration, and industry and information technology systems; leaders of the Boao Lecheng International Medical Tourism Pilot Zone Administration; and leaders of the Haikou Municipal Government. Attendees also include representatives from renowned domestic and international pharmaceutical and medical device companies, contract research organizations (CROs), contract manufacturing organizations (CMOs), and other pharmaceutical R&D service and production outsourcing enterprises, as well as representatives from leading pharmaceutical companies within the province.

(VII) Parallel Forum 4: China Anti-Aging Industry Development Forum

Scale:Approximately 400 people

Content: Hosted by the China Anti-Aging Promotion Association, the event invites leaders from relevant national, provincial, and municipal departments; representatives of the host and organizing entities; local Hainan officials; medical institutions; universities; anti-aging organizations; scientific research and testing institutions; and cosmetics companies.

(8) Parallel Forum 5: High-Level Summit on Innovative Vaccine R&D and Application

Scale:Approximately 200 people

Content:Hosted by the Chinese Preventive Medicine Association, the event invites representatives from China’s Centers for Disease Control and Prevention (CDCs), industry leaders, and renowned experts and scholars to discuss the latest and most cutting-edge topics, including emerging trends in the vaccine industry, business strategies, internationally leading R&D and manufacturing technologies, recent advancements and breakthroughs in vaccine development, and collaboration opportunities. The conference aims to provide a platform for learning and exchange among professionals in the vaccine sector, fostering industry-academia-research cooperation both domestically and internationally.

(9) Parallel Forum 6: Global Summit on Innovative Cancer Therapies

Scale:Approximately 300 people

Content:Co-hosted by the China Anti-Cancer Association and the Hainan Provincial Anti-Cancer Association, the event invites representatives from government departments, renowned experts, presidents of oncology hospitals, medical professionals, and pharmaceutical company executives to attend.

(10) Parallel Forum 7: Innovative Drug Market Access Policy Sharing Forum

Scale:Approximately 200 people

Content:The event is proposed to be co-hosted by the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration and the China Pharmaceutical Innovation Promotion Association, inviting experts, scholars, entrepreneurs, and media representatives from the fields of medicine and health, pharmaceutical policy and management, and clinical pharmacy.

(11) Parallel Forum 8: Seminar on Investment and Financing for Innovative Biologics

Scale:Approximately 200 people

Content:Co-hosted by the Chinese Society for Biotechnology and the China Chamber of Commerce for Import and Export of Medicines and Health Products, the event invites experts from diverse fields—including heads of pharmaceutical industrial parks, renowned economists, domestic and international experts in biomedical innovation research, industry elites in capital operations, representatives of successfully listed companies that have secured financing, and private equity investors—to deliver keynote speeches and engage in discussions and exchanges.

(12) Parallel Forum 9: Forum on Healthcare Security Reform and Development in Free Trade Zones (Ports)

Scale:Approximately 150 people

Content:Hosted by the Hainan Provincial Social Security Research Association, the event invited heads of medical insurance administrative and operating agencies, representatives from medical institutions, and experts and scholars from academic institutions to actively offer advice and suggestions. In-depth exchanges and discussions were conducted on issues such as innovation in the medical insurance system, improvement of the multi-tiered medical security system, reform of medical insurance payment mechanisms, centralized procurement of pharmaceuticals and medical supplies, coordinated reforms across healthcare, medical insurance, and pharmaceutical sectors, local legislation, and fund supervision.

(13) Parallel Forum 10: Forum on High-Quality Hospital Development

Scale:Approximately 300 people

Content:Organized by the Hainan Provincial Hospital Association and supported by the Chinese Hospital Association, this event brings together representatives from various hospitals, leaders from health administrative systems, officials from national ministerial-level research institutions or associations, leading technology executives, and renowned experts and scholars. It focuses in depth on the high-quality development of hospitals, accurately grasps the dynamics and future trends of hospital development, and offers recommendations and support for establishing and improving China’s hospital system.

(14) Parallel Forum 11: Special Investment Promotion Conference for the Medical and Health Industry in the Hainan Free Trade Port

Scale:Approximately 100 people

Content:Organized by the China Medical Finance Industry Alliance and the Hainan Provincial Committee of the China Council for the Promotion of International Trade, and undertaken by YiBan JinFu and Hailv Exhibition, this event invites participation from government agencies, pharmaceutical industrial parks, medical institutions, members of the Medical Finance Industry Alliance, medical industry associations, senior executives of listed healthcare companies, medical trade enterprises, healthcare industry funds, hospitals, and medical commercial companies.

Conference Theme Forum ‹‹‹‹‹‹

Forum 1: Forum on Innovative R&D of Small-Molecule Drugs

Forum 2: Design and Application of Self-Replicating mRNA

Forum 3: Recombinant Therapeutic Biologics Forum

Forum 4: Forum on Oncology Drug R&D and Preclinical Safety Evaluation

Forum 5: Translational Strategies and Case Studies in Oncology Drug Development

Forum 6: Tumor Neoantigen Vaccine Forum

Forum 7: Forum on the Interpretation of Chinese and International Regulations for Cell and Gene Therapy

Forum 8: Forum on the Application of Mass Spectrometry Technology in Life Sciences

Forum 9: Quality and Analytics Forum

Forum 10: Formulation Development Forum

Forum 11: Early Clinical and Translational Medicine Research Forum

Forum 12: Vaccination Forum

Forum 13: Vaccine Quality and R&D Forum

Forum 14: Special Symposium on the Clinical Application of Blood Products

Forum 15: CMC and Commercialization of Novel Conjugate Drugs

Forum 16: Development of Novel Anti-Cancer mRNA Nanovaccines

Forum 17: Extrahepatic Delivery of Oligonucleotide Therapeutics Forum

Forum 18: Small Molecule Drug Formulation Development Forum

Forum 19: Forum on Differentiated Development of Innovative Small-Molecule Drugs

Forum 20: The Future Path to Industrialization of Cell Therapy Drugs

Forum 21: Molecular Design and Development Forum for Cell Therapy

Forum 22: Forum on Process Development, Manufacturing, and Optimization Change Strategies for Cell Therapy Products

Forum 23: Risk Assessment and Quality Testing of Cell Therapy Products Forum

Forum 24: Forum on Leading Practices in the Industrialization and Commercialization of Cellular Immunotherapy

Forum 25: New Therapies in Cell and Gene Therapy Forum

Forum 26: Cell Engineering and Organ Regeneration Forum

Forum 27: Universal/iPSC-Derived Cell Therapy Forum

Forum 28: Bispecific Antibody and ADC Molecular Design Forum

Forum 29: Laboratory Animal Forum

Forum 30: Challenges and Latest Advances in CAR-T Therapy for Solid Tumors

Forum 31: Biopharmaceutical Engineering Technology Forum

Forum 32: Digital Transformation in Biopharma Forum

Forum 33: Forum on the Application of AI in the Biopharmaceutical Field

Forum 34: Biopharmaceutical Supply Chain Development Forum

Forum 35: Biomedical Big Data and Artificial Intelligence Forum

Forum 36: Special Session on Bioimaging Technologies

Forum 37: Conference on Spectroscopic Technologies in Life Sciences

Forum 38: Neuroscience and Brain-Computer Interface Forum

Forum 39: Progress and Trends in the Global Development of Novel Anticancer Drugs—The Promising Future of Conjugate Drugs

Forum 40: Organ-on-a-Chip and Precision Medicine Forum

Forum 41: Special Session on New Combinations of Conjugated Drugs

Forum 42: Immune Cell Therapy Forum

Forum 43: Forum on Advances in the Application of Flow Cytometry in Laboratory Medicine

Forum 44: Clinical Medicine and Translational Medicine Forum

Forum 45: Clinical Medicine and Clinical Operations Forum

Forum 46: Preclinical Research Forum: Preclinical Evaluation of Advanced Therapies

Forum 47: Preclinical Research Forum: Applications of Organoids in Efficacy & Toxicology

Forum 48: Clinical Development Forum: Anti-infectives, ADC

Forum 49: Clinical Development Forum: Future Layout of the ADC Track from a Clinical Perspective

Forum 50: Clinical Development Forum: Differentiated Development by MNCs and Local Pharmaceutical Companies

Forum 51: Organoids and 3D Cell Culture Forum

Forum 52: The New Future of Antibody Drugs Forum

Forum 53: Antibody Upstream and Downstream Process Development Forum

Forum 54: Gene Therapy Forum Focus: Clinical Exploration and Industrialization Layout

Forum 55: Gene Therapy Forum Focus: Technological Innovation and Expansion of Indications

Forum 56: Gene Therapy Technology Innovation and R&D Forum

Forum 57: Application Scenarios, Pipeline, and Prospects of Circular RNA

Forum 58: Nucleic Acid Drug Development Forum

Forum 59: Focus on Nucleic Acid Therapeutics: Applications and Commercialization Strategy Forum

Forum 60: Forum on the Future Industrial Development of Synthetic Biology

Forum 61: Forum on the R&D and Commercialization of Gene Therapy Drugs for Rare Diseases

Forum 62: Process Development Forum—Antibody Drugs

Forum 63: Forum on Innovative Development of Stem Cell Therapy

Forum 64: Stem Cells and Regenerative Medicine – Forum on Technological Platforms and Clinical Translation

Forum 65: Forum on Innovative Development in Molecular Biology

Forum 66: Peptide Drug Development Forum—From Molecular Structure to Industrial-Scale Production

Forum 67: Proteomics Forum

Forum 68: Single-Cell and Spatial Omics Session

Forum 69: Frontier Forum on Single-Cell Multi-Omics

Forum 70: Metabolomics Forum

Forum 71: Innovative Biologics Clinical Research Forum

Forum 72: Forum on the Development of Innovative Radiopharmaceuticals

Forum 73: Symposium on the Application of Surface Analysis Techniques in the Biopharmaceutical Field

Forum 74: Special Session on Epigenetics and Epigenomics

Forum 75: Advances in Targeted LNPs for Tumor Vaccine Development

Forum 76: Innovative Technology Platforms for Target Screening (Proteomics, CRISPR, Transposons, etc.)

Forum 77: Forum on Delivery and Clinical Progress of mRNA Cancer Vaccines

Forum 78: LNP Delivery Systems and In Vivo Gene Editing Forum

Forum 79: Forum on Advances in DNA and RNA Research

Forum 80: Advanced Manufacturing Forum for CGT Products

Forum 81: AI-Empowered Drug R&D Forum

Forum 82: ADC Drug R&D and Clinical Session

Audience from ««««««

Industry Distribution

● Cell and Gene Therapy

● Biotechnology Company

●CDMO

● Drug Testing

● Companion Diagnostics

● Cold Chain Services

● Cleanroom Equipment Suppliers

● Packaging Machinery

● Industrial Park

● Investment Institutions

● Biopharmaceutical Companies

● Preclinical/Clinical R&D CRO

● Upstream and Downstream Bioprocessing Solutions

● Life Sciences and Analytical Instruments

● Analytical Services

● Laboratory Equipment Supplier

● Intermediates and Active Pharmaceutical Ingredients

● Formulation Machinery

● Consulting Firms and Law Firms

Position Distribution

President, Vice President, CEO, and Directors, General Managers, Deputy General Managers, and Supervisors of the following departments:

● R&D

● Business Development Department

● Antibody Development Platform

● Authorization and Assignment

● Clinical and Preclinical Development

● Production

● Quality Assurance and Quality Control

● External Development and Collaboration

●Biologics Division

● Immunotherapy

●Regulatory Affairs

● Process Development

● Contract Manufacturing

● Marketing Department

Partner Media ‹‹‹‹‹‹

Past Editions ‹‹‹‹‹‹

Contact Information ‹‹‹‹‹‹

Address: Rooms 401-402, Building T6, Haissi Knowledge Center, Sino-Singapore Guangzhou Knowledge City, Huangpu District, Guangzhou

Contact: Ms. Wang17774983530

Email: 815625716@qq.com